Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS) (English, HTML)

Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS): English HTML file. From Health Canada, updated May 2024. View metadata, licence and the direct download on CanQuery.

Format
HTML
Access
Original download only
Publisher-reported update
2024-05-10

Health Canada carried out a safety review after finding international cases of DRESS suspected of being linked with the use of Uloric (febuxostat). DRESS describes a group of rare, but serious and potentially life-threatening, side effects of a medication, with symptoms such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc. These reactions usually happen two weeks to two months after starting a medication.

Access original file

Data overview

Formats
HTML
File languages
English
Available actions
Access original file

Official sources and licences

Related open data